Guggenheim Boosts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $1,000.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target upped by equities researchers at Guggenheim from $995.00 to $1,000.00 in a research note issued on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Guggenheim’s price objective suggests a potential upside of 53.57% from the stock’s current price.

REGN has been the topic of a number of other research reports. HSBC lowered their target price on Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating on the stock in a report on Monday, July 6th. Leerink Partners restated a “market perform” rating and issued a $641.00 price objective (down from $792.00) on shares of Regeneron Pharmaceuticals in a research report on Monday, May 18th. Wells Fargo & Company decreased their price objective on Regeneron Pharmaceuticals from $800.00 to $700.00 and set an “equal weight” rating on the stock in a research note on Monday, May 18th. Sanford C. Bernstein dropped their price objective on Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating for the company in a research report on Wednesday, April 8th. Finally, Cantor Fitzgerald cut their target price on shares of Regeneron Pharmaceuticals from $785.00 to $750.00 and set an “overweight” rating for the company in a research note on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $787.88.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $651.18 on Tuesday. The company has a current ratio of 3.57, a quick ratio of 2.96 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $68.84 billion, a P/E ratio of 15.87, a price-to-earnings-growth ratio of 1.50 and a beta of 0.24. The firm has a 50-day moving average price of $637.84 and a two-hundred day moving average price of $715.73. Regeneron Pharmaceuticals has a twelve month low of $541.00 and a twelve month high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.91 by $0.56. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The company had revenue of $3.61 billion for the quarter, compared to the consensus estimate of $3.48 billion. During the same quarter in the prior year, the firm earned $8.22 earnings per share. The company’s revenue for the quarter was up 19.0% compared to the same quarter last year. As a group, research analysts expect that Regeneron Pharmaceuticals will post 37.12 earnings per share for the current fiscal year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 200 shares of the firm’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total transaction of $130,030.00. Following the sale, the director owned 17,303 shares in the company, valued at $11,249,545.45. This trade represents a 1.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Large investors have recently added to or reduced their stakes in the business. Insigneo Advisory Services LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 3.0% in the fourth quarter. Insigneo Advisory Services LLC now owns 445 shares of the biopharmaceutical company’s stock valued at $343,000 after purchasing an additional 13 shares in the last quarter. Guardian Wealth Advisors LLC NC boosted its position in Regeneron Pharmaceuticals by 3.3% during the 4th quarter. Guardian Wealth Advisors LLC NC now owns 443 shares of the biopharmaceutical company’s stock worth $342,000 after acquiring an additional 14 shares during the period. Arjuna Capital boosted its position in Regeneron Pharmaceuticals by 3.2% during the 1st quarter. Arjuna Capital now owns 457 shares of the biopharmaceutical company’s stock worth $353,000 after acquiring an additional 14 shares during the period. TD Private Client Wealth LLC grew its stake in Regeneron Pharmaceuticals by 9.7% during the 4th quarter. TD Private Client Wealth LLC now owns 169 shares of the biopharmaceutical company’s stock valued at $130,000 after acquiring an additional 15 shares in the last quarter. Finally, MCF Advisors LLC grew its stake in Regeneron Pharmaceuticals by 50.0% during the 4th quarter. MCF Advisors LLC now owns 45 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 15 shares in the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Guggenheim raised its price target on Regeneron to $1,000 from $995 and reiterated a buy rating, signaling continued confidence in the company’s longer-term upside. Benzinga
• Neutral Sentiment: Regeneron also provided an update that its mid-stage POTS study for REGN7544 has wrapped up, but the article does not include enough detail to gauge the readout’s financial or clinical impact yet. TipRanks
• Negative Sentiment: Several firms, including Bronstein, Gewirtz & Grossman, Bernstein Liebhard, Bleichmar Fonti & Auld, Pomerantz, the Schall Law Firm, and others, announced or promoted a class action lawsuit against Regeneron over alleged securities-law violations tied to trial disclosures and the subsequent stock decline, keeping legal risk in focus for investors. PR Newswire

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.